GO
Loading...

Gilead Sciences Inc

More

  • Midday Glance: Biotechnology companies Thursday, 21 Aug 2014 | 1:22 PM ET

    Amgen Inc. rose$. 03 or percent, to $132.71. Biogen Idec fell $2.14 or. 6 percent, to $340.45. Celgene Corp. rose$. 02 or percent, to $92.02.

  • Final Glance: Biotechnology companies Wednesday, 20 Aug 2014 | 6:02 PM ET

    Amgen Inc. fell$. 34 or. 3 percent, to $132.68. Biogen Idec fell $3.26 or. 9 percent, to $342.58. Celgene Corp. rose$. 64 or. 7 percent, to $92.00.

  • Midday Glance: Biotechnology companies Wednesday, 20 Aug 2014 | 1:49 PM ET

    Amgen Inc. fell$. 35 or. 3 percent, to $132.67. Biogen Idec fell $2.66 or. 8 percent, to $343.18. Celgene Corp. rose $1.38 or 1.5 percent, to $92.74.

  • Early Glance: Biotechnology companies Wednesday, 20 Aug 2014 | 12:21 PM ET

    Amgen Inc. fell$. 61 or. 5 percent, to $132.41. Biogen Idec fell $1.68 or. 5 percent, to $344.16. Celgene Corp. rose $1.47 or 1.6 percent, to $92.83.

  • Final Glance: Biotechnology companies Tuesday, 19 Aug 2014 | 6:08 PM ET

    Amgen Inc. fell$. 20 or. 2 percent, to $133.02. Biogen Idec rose $1.24 or. 4 percent, to $345.84. Celgene Corp. rose$. 05 or. 1 percent, to $91.36.

  • Midday Glance: Biotechnology companies Tuesday, 19 Aug 2014 | 4:03 PM ET

    Amgen Inc. fell $1.29 or 1.0 percent, to $131.93. Biogen Idec fell$. 31 or. 1 percent, to $344.29. Celgene Corp. rose$. 10 or. 1 percent, to $91.41.

  • Final Glance: Biotechnology companies Monday, 18 Aug 2014 | 6:02 PM ET

    Amgen Inc. rose$. 42 or. 3 percent, to $133.22. Biogen Idec rose $2.13 or. 6 percent, to $344.60. Celgene Corp. rose $1.71 or 1.9 percent, to $91.31.

  • Early Glance: Biotechnology companies Monday, 18 Aug 2014 | 10:29 AM ET

    Amgen Inc. rose $1.09 or. 8 percent, to $133.89. Biogen Idec rose $3.18 or. 9 percent, to $345.65. Celgene Corp. rose $1.70 or 1.9 percent, to $91.30.

  • LOS ANGELES, Aug 17- Biotech drug production techniques based on plants, which may prove to be faster, higher yielding and cheaper than current methods using mammalian cells, haven't caught on with the biggest pharmaceutical companies.

  • Final Glance: Biotechnology companies Friday, 15 Aug 2014 | 6:16 PM ET

    Amgen Inc. rose$. 94 or. 7 percent, to $132.80. Biogen Idec rose $5.46 or 1.6 percent, to $342.47. Celgene Corp. rose $1.15 or 1.3 percent, to $89.61.

  • *VIX jumps on Russia, Ukraine concerns. NEW YORK, Aug 15- U.S. stocks ended mixed on Friday, paring an earlier selloff sparked by reports of Ukraine shelling a Russian armored column.

  • Nordstrom and Gilead are big market movers Friday, 15 Aug 2014 | 4:22 PM ET

    NEW YORK— Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:. Nordstrom Inc., down $3.58 to $65.11. Dillard's Inc., down $9.49 to $106.11.

  • Most active Nasdaq-traded stocks Friday, 15 Aug 2014 | 1:16 PM ET

    Apple Inc. rose. 5 percent to $97.98 with 47,885,600 shares traded. Applied Materials Inc. rose 6.3 percent to $22.48 with 24,764,100 shares traded. Cisco Systems Inc. fell. 4 percent to $24.43 with 32,750,700 shares traded.

  • Midday Glance: Biotechnology companies Friday, 15 Aug 2014 | 1:15 PM ET

    Amgen Inc. fell$. 50 or. 4 percent, to $131.36. Biogen Idec rose$. 93 or. 3 percent, to $337.94. Celgene Corp. rose$. 77 or. 9 percent, to $89.23.

  • Aug 15- Gilead Sciences Inc said an arbitration panel rejected Roche Holding AG's patent infringement claims related to Gilead's hepatitis C drug, Sovaldi.

  • Early Glance: Biotechnology companies Friday, 15 Aug 2014 | 11:21 AM ET

    Amgen Inc. fell$. 65 or. 5 percent, to $131.21. Biogen Idec rose $1.59 or. 5 percent, to $338.60. Celgene Corp. rose $1.25 or 1.4 percent, to $89.71.

  • Aug 15- Achillion Pharmaceuticals Inc said all patients treated with its experimental hepatitis C drug showed no detectable levels of the virus four weeks after the therapy, sending its shares up 18 percent. Achievement of 100 percent cure rate confirms the competitive profile of NS5A, Wells Fargo Securities analyst Brian Abrahams wrote in a note.

  • Achillion rises on hepatitis C drug study Friday, 15 Aug 2014 | 9:05 AM ET

    NEW YORK— Achillion Pharmaceuticals climbed in premarket trading Friday after the company reported promising results from a small clinical trial of an experimental hepatitis C drug. Shares of Achillion Pharmaceuticals Inc. jumped $1.55, or 18.4 percent, to $9.99 in premarket trading about 30 minutes before the market opening.

  • Gilead says wins favorable ruling on hep C drug Friday, 15 Aug 2014 | 8:10 AM ET

    Aug 15- Gilead Sciences Inc said an arbitration panel has ruled in its favor, rejecting patent infringement claims from Roche Holding AG, related to Gilead's hepatitis C drug, Sovaldi.

  • Aug 15- Achillion Pharmaceuticals Inc said interim results from a mid-stage trial showed that all patients given its experimental hepatitis C drug showed no detectable levels of the virus four weeks after completing the therapy.